What is the recommended management of acute pyelonephritis in a non‑pregnant adult, including empiric oral therapy and criteria for intravenous treatment?

Management of Acute Pyelonephritis in Non-Pregnant Adults

For outpatient management of uncomplicated acute pyelonephritis, use oral fluoroquinolones (ciprofloxacin 500-750 mg twice daily for 7 days or levofloxacin 750 mg daily for 5 days) as first-line therapy, but only if local fluoroquinolone resistance is <10%; otherwise, give an initial IV dose of ceftriaxone 1-2 g followed by oral cephalosporins for 10 days. 1

Initial Assessment and Risk Stratification

The critical first decision is determining whether the patient requires hospitalization or can be managed as an outpatient. This distinction fundamentally changes the treatment approach.

Diagnostic Workup

Always obtain before starting antibiotics:

• Urinalysis (white blood cells, red blood cells, nitrite)
• Urine culture with antimicrobial susceptibility testing 1

Imaging indications:

• Ultrasound for patients with history of urolithiasis, renal dysfunction, or high urine pH 1
• CT scan or excretory urography if patient remains febrile after 72 hours of treatment OR immediate imaging if clinical deterioration occurs 1

This imaging timeline is crucial—waiting 72 hours for persistent fever is appropriate, but any clinical worsening demands immediate imaging to rule out obstruction, abscess, or emphysematous pyelonephritis, which can rapidly progress to urosepsis 1.

Outpatient Oral Therapy

First-Line Options (Local Resistance Matters)

Fluoroquinolones (only if local E. coli resistance <10%):

• Ciprofloxacin 500-750 mg twice daily for 7 days 1
• Levofloxacin 750 mg once daily for 5 days 1

The 2024 EAU guidelines emphasize that fluoroquinolones and cephalosporins are the only antimicrobials recommended for oral empiric treatment 1. The JAMA 2024 consensus supports 5-7 day fluoroquinolone courses based on multiple RCTs showing comparable outcomes 2.

Oral Cephalosporins (when fluoroquinolone resistance is high):

• Cefpodoxime 200 mg twice daily for 10 days 1
• Ceftibuten 400 mg once daily for 10 days 1

Critical caveat: When using oral cephalosporins empirically, you must give an initial IV dose of a long-acting parenteral antimicrobial (e.g., ceftriaxone 1-2 g) because oral cephalosporins achieve significantly lower blood and urinary concentrations than IV formulations 1.

Alternative (less preferred):

• Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days (note the longer duration) 1

Agents to AVOID for Pyelonephritis

Do not use nitrofurantoin, oral fosfomycin, or pivmecillinam—insufficient efficacy data for upper tract infections 1.

Inpatient IV Therapy

Indications for Hospitalization

• Complicated infections
• Sepsis or hemodynamic instability
• Persistent vomiting (cannot tolerate oral therapy)
• Failed outpatient treatment
• Extremes of age
• Immunocompromised state 3, 4

IV Antibiotic Regimens

First-line empiric IV options:

• Ciprofloxacin 400 mg twice daily 1
• Levofloxacin 750 mg once daily 1
• Ceftriaxone 1-2 g once daily (higher dose recommended) 1
• Cefepime 1-2 g twice daily (higher dose recommended) 1
• Piperacillin/tazobactam 2.5-4.5 g three times daily 1
• Aminoglycosides: Gentamicin 5 mg/kg once daily or Amikacin 15 mg/kg once daily (with or without ampicillin) 1

Reserve carbapenems and novel broad-spectrum agents (meropenem, imipenem, ceftolozane/tazobactam, ceftazidime/avibactam) only for patients with early culture results showing multidrug-resistant organisms 1. This antimicrobial stewardship principle is critical to prevent ecological collateral damage 2.

Treatment Duration

The 2024 JAMA consensus provides clear guidance: 7 days of treatment is adequate for most cases 2. Multiple RCTs demonstrate that 7-day regimens are comparable to 14-day courses for clinical and microbiological outcomes. For gram-negative bacteremia from a urinary source, 7 days is also sufficient 2.

Transition to Oral Therapy

Once clinically improved (afebrile, tolerating oral intake), transition from IV to oral antibiotics to complete the 7-day course. Tailor the oral agent based on culture susceptibility results.

Follow-Up and Treatment Failure

Repeat urine culture 1-2 weeks after completing antibiotics 3.

If patient remains febrile after 72 hours or deteriorates:

• Obtain imaging immediately (CT scan preferred) 1
• Repeat blood and urine cultures
• Consider resistant organisms, anatomic abnormalities, obstruction, abscess formation, or immunosuppression 3, 4
• May require antibiotic change or surgical intervention (percutaneous drainage, nephrostomy) 4

Common Pitfalls

1. Using nitrofurantoin or fosfomycin for pyelonephritis—these lack adequate tissue penetration for upper tract infections 1

2. Prescribing oral cephalosporins without an initial IV dose—this compromises early therapeutic levels 1

3. Ignoring local resistance patterns—fluoroquinolones should not be used if local resistance exceeds 10% 1

4. Delaying imaging in deteriorating patients—obstruction can rapidly progress to sepsis 1

5. Treating for 14 days when 7 days is sufficient—this increases adverse effects and resistance without improving outcomes 2

6. Using broad-spectrum agents empirically—reserve carbapenems for documented resistant organisms to preserve their efficacy 2, 1